S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48

Kiromic BioPharma Stock Forecast, Price & News

-0.16 (-12.40%)
(As of 01/19/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
280,784 shs
Average Volume
98,982 shs
Market Capitalization
$17.44 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive KRBP News and Ratings via Email

Sign-up to receive the latest news and ratings for Kiromic BioPharma and its competitors with MarketBeat's FREE daily newsletter.

Kiromic BioPharma logo

About Kiromic BioPharma

Kiromic BioPharma, Inc., a target discovery and gene editing company, focuses on developing immuno-oncology therapeutics for the treatment of blood cancers and solid tumors. The company develops ALEXIS-ISO-1, an allogenic gamma delta CAR-T cell therapy product candidate targeting Isomesothelin; ALEXIS-PRO-1, an allogeneic gamma delta chimeric T cell therapy product candidate targeting PD-L1; and chimeric gamma delta PD1 T cell switch receptor therapy. It has license agreements with Mercer University; CGA 369 Intellectual Holdings, Inc.; and Longwood University, as well as research and development collaboration agreements with Molipharma, S.R.L. and Leon Office (H.K.). The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.


Kiromic Biopharma Inc.
August 11, 2021 |  barrons.com
See More Headlines

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
Book Value
$1.55 per share


Net Income
$-19.20 million
Pretax Margin




Free Float
Market Cap
$17.44 million
Not Optionable

Company Calendar

Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

1.46 out of 5 stars

Medical Sector

1108th out of 1,415 stocks

Biological Products, Except Diagnostic Industry

172nd out of 206 stocks

Analyst Opinion: 0.0Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Kiromic BioPharma (NASDAQ:KRBP) Frequently Asked Questions

Are investors shorting Kiromic BioPharma?

Kiromic BioPharma saw a decline in short interest during the month of December. As of December 31st, there was short interest totaling 56,900 shares, a decline of 68.0% from the December 15th total of 177,700 shares. Based on an average trading volume of 405,500 shares, the days-to-cover ratio is presently 0.1 days.
View Kiromic BioPharma's Short Interest

When is Kiromic BioPharma's next earnings date?

Kiromic BioPharma is scheduled to release its next quarterly earnings announcement on Wednesday, March 30th 2022.
View our earnings forecast for Kiromic BioPharma

Who are Kiromic BioPharma's key executives?

Kiromic BioPharma's management team includes the following people:
  • Dr. Maurizio Chiriva Internati Ph.D., Chairman, CEO & Pres (Age 53, Pay $437.9k)
  • Mr. Tony Tontat, CFO & Director (Age 55, Pay $5.39M)
  • Mr. Gianluca Rotino, Chief Strategy and Innovation Officer & Director (Age 49, Pay $4.81M)
  • Mr. Ignacio Nunez, Chief Operating & Manufacturing Officer
  • Dr. David M. Spencer, Chief Scientific Officer (Age 59)
  • Dr. Scott Dahlbeck Pharm.D., M.D., PharmD, Chief Medical Officer (Age 59)

When did Kiromic BioPharma IPO?

(KRBP) raised $16 million in an IPO on Friday, October 16th 2020. The company issued 1,200,000 shares at $12.00-$14.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO and Paulson Investment Company was co-manager.

What is Kiromic BioPharma's stock symbol?

Kiromic BioPharma trades on the NASDAQ under the ticker symbol "KRBP."

How do I buy shares of Kiromic BioPharma?

Shares of KRBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kiromic BioPharma's stock price today?

One share of KRBP stock can currently be purchased for approximately $1.13.

How much money does Kiromic BioPharma make?

Kiromic BioPharma has a market capitalization of $17.44 million. The company earns $-19.20 million in net income (profit) each year or ($1.89) on an earnings per share basis.

How many employees does Kiromic BioPharma have?

Kiromic BioPharma employs 19 workers across the globe.

What is Kiromic BioPharma's official website?

The official website for Kiromic BioPharma is www.kiromic.com.

How can I contact Kiromic BioPharma?

The company can be reached via phone at 832-968-4888 or via email at [email protected].

This page was last updated on 1/20/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.